Interview: ViroMed On Pricing, Manufacturing World’s First Broadly Used Gene Therapy
Executive Summary
The head of global business strategy at ViroMed, one of the gene therapy companies nearing the commercial stage in the US, talks exclusively to Scrip about the South Korean biotech’s strategies, including for pricing and manufacturing, which are emerging as key considerations for developers.
You may also be interested in...
Stempeutics Eyes Global Markets For New Crohn's Symptom Cell Therapy
Stempeutics explores stem cell therapy in India for Crohn’s disease-related perianal fistulae while considering entry into other Asian markets.
Finance Watch: Third Rock Raises $770m To Launch Up To 12 New Companies
The VC firm known for its new company formation efforts will launch 10-12 biopharma, device and diagnostic ventures with its fifth fund. Also, EpimAb raises a $74m series B round, three more drug developers join the IPO queue and Amicus leads recent follow-on offerings.
Korean Gene Therapies On Horizon, But Slow Regulatory Changes A Drag
While Korean companies are actively pursuing development of gene therapies, various regulatory restrictions at home are keeping them from speeding up development. But global development continues apace, with interim Phase III results for some expected later this year.